Prevalence of Nasal colonization with *Staphylococcus aureus* in 4 cities in Peru

Joan Neyra\(^1\)*, Michael Ellis\(^2\), Claudio Rocha\(^1\), Juan Silvera\(^3\), Moisés Apolaya\(^3\), Maruja Bernal\(^1\), Rina Meza\(^1\), Enrique Canal\(^1\), Yocelinda Meza\(^1\) and David Blazes\(^4\)

### Abstract

**Background:** Antimicrobial resistance (AMR) is a growing public health threat around the world and is not well characterized in the developing setting. Specifically, there is a lack of information regarding nasal colonization with *S. aureus* and methicillin-resistant *Staphylococcus aureus* (MRSA) in Latin America and Peru.

**Methods:** This is the report of the baseline findings of a prospective cohort study followed up over 1 year at four geographically and ecologically distinct Peruvian Air Force bases in order to determine *S. aureus* nasal colonization prevalence and risk factors. Additionally, all MRSA isolates underwent molecular analysis which included pulsed-field gel electrophoresis and determination of virulence and resistance genes.

**Results:** We enrolled 756 military personnel. Anterior nares colonization with *Staphylococcus aureus* was detected in 73 of 756 participants (9.7 %) and MRSA was detected in 2 of 756 (0.3 %). Colonization rates differed significantly (\(P = 0.02\)) between geographic enrollment sites: Talara-4.3 %, Iquitos-9.1 %, Arequipa-14.0 % and Lima-11.3 %. Risk factors for *S. aureus* colonization included being male and a reported history of respiratory disease.

**Conclusion:** Overall, we found low prevalence of *S. aureus* and MRSA nasal colonization in this Peruvian military population. These findings contribute to the overall epidemiological understanding of *S. aureus* and MRSA in Latin America. The colonization rates which varied based on geographical location warrants further study.

**Keywords:** Antimicrobial resistance, Methicillin-resistant *Staphylococcus aureus*, Military personnel

### Background

The increasing prevalence of methicillin-resistant *Staphylococcus aureus* is a global problem, affecting military and non-military populations around the world. MRSA was first documented in 1960, and until the late 1990s, its presence was confined largely to hospital settings with occasional outbreaks. Since then, the number of outbreaks and infections caused by MRSA, specifically community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA) strains increased steadily [1, 2]. USA300 genotype is the predominant CA-MRSA strain recovered from outbreak investigations in U.S. and different countries in Europe and Asia, such as Japan [3], constituting a common cause of community associated skin and soft tissue infections (SSTIs).

Nasal colonization with *Staphylococcus aureus* or MRSA is a risk factor for subsequent infection by these bacteria [4, 5]. In non-Latin American populations, colonization status varies with approximately 20–30 % persistently colonized and 20 % is intermittently colonized [6–8]. Colonization is facilitated by the anatomy of the nasal vestibule and the resistance of *S. aureus* to microbicide peptides in the mucus [9]. Nasal colonization appears to change during one’s lifetime. Colonization begins shortly after birth, decreases during the first 5 years and then it increases until 50 % are carriers between 6 and 12 years; and finally it decreases as children mature and become adults [10]. In the military setting, *Staphylococcus aureus* infections complicate combat-related injuries and produce skin and soft-tissue infections during deployments or training. Among U.S. soldiers, MRSA SSTIs represent a considerable burden, and nasal colonization is a risk factor for subsequent disease [1, 11–14]. For example, the cumulative incidence of SSTIs after 10 weeks of
follow-up at training facilities in U.S. military trainees was 38% in MRSA-colonized subjects while in non-colonized it was only 2% [11]. The Centers for Disease Control and Prevention’s (CDC) 2013 report on antibiotic resistant pathogens listed MRSA as one of the most serious threats, causing 80,461 severe infections and 11,285 deaths per year in the U.S., leading to a heavy burden of the healthcare system [15]. Similarly, the 2014 WHO Global Health Report on Antimicrobial Resistance reported that in all the WHO regions, MRSA prevalence of infections was above 20% and increased the risk of death and the associated healthcare costs [16, 17]. In Latin America, a surveillance network for resistant bacterial infections was organized in 1998 under Pan American Health Organization (PAHO) sponsorship; collecting data from specific national and regional hospitals with adequate laboratory infrastructure and resources. However, there is little information regarding the prevalence in other areas, so the geographic extent and the characteristics of MRSA infections in Latin America are not well described in terms of prevalence, isolates, and risk factors [18]. Our current knowledge indicates that four MRSA clones are the most prevalent in Latin America: Brazilian, Pediatric, Cordobes/Chilean and New York/Japan, with marked differences in virulence, antimicrobial resistance profile and geographical distribution [19].

In Peru, current information about MRSA is mostly limited to case reports or series from hospital-based samples from reference hospitals with appropriate protocols for lab procedures and resources. Unfortunately, these studies do not inform us about the prevalence of S. aureus nasal colonization nor the epidemiological characteristics in the community, especially in young at-risk populations such as military personnel. Our work was the first study to systematically determine the prevalence and the molecular characteristics of nasal colonization with Staphylococcus aureus and MRSA among a Peruvian military population in multiple cities in Peru. Herein, we report the baseline results of this study.

Methods
Study design
We conducted a prospective cohort study with 1 year of follow-up among active duty military personnel from four bases one in each region of the Peruvian Air Force (Lima, Arequipa, Talara, and Iquitos). This is the report of the baseline findings of this cohort. The study population included male and female military active duty personnel, between age 18 and 59 years, stationed at these bases with different climate characteristics (Iquitos is located in the jungle; Talara, in the northern desert coast, Lima at the central coast with mild to warm temperatures depending on the season, and Arequipa, which is located at high altitude in the southern highlands, with a dry and relatively cold climate). See Fig. 1.

Study procedures
We enrolled military personnel from four large bases in each Air Force region. After we obtained written informed consent, each participant completed a self-administered questionnaire about demographic and risk factors and provided a nasal swab. Investigators obtained a sample from the vestibular area of each of the nares, using BD BBL CultureSwabs® (BD Diagnostic, Sparks MD). Each nasal swab specimen was placed in a refrigerated container and later stored in a refrigerator at 4 °C until the time of the shipping to Naval Medical Research Unit-6 lab (NAMRU-6). Once they arrived at NAMRU-6 Bacteriology lab, the time gap between sample collection and plating was 1 month.

Lab procedures
Labeled swabs were shipped to the Naval Medical Research Unit N° 6 (NAMRU-6) located at Lima, Peru. Nasal culture specimens were placed in 5 ml of tryptic soy broth (TSB) supplemented with 6.5% NaCl and incubated for 18-24 h at 35 °C. After that time, a 75 microL aliquot was plated onto mannitol salt agar. Plates were incubated for up to 48 h at 37 °C and inspected for yellow colonies characteristic of S. aureus. Identified isolates were sub cultured onto tryptic soy agar with 5% sheep blood. Subsequent colonies underwent catalase and coagulase testing per Micro Lab Standard Operational Procedures (SOP) at NAMRU-6. All confirmed S. aureus isolates collected from the nasal swabs were shipped to Uniformed Services University (USU)’s Laboratory where they underwent susceptibility testing using disk diffusion tests for identifying MRSA strains, following the standards established by the Clinical and Laboratory Standards Institute [20]. Additionally, all MRSA strains underwent pulsed field gel electrophoresis (PFGE) procedures. Using polymerase chain reaction (PCR) we detected Panton-Valentine Leukocidin (PVL), arginine catabolic mobile element (ACME), staphylococcal chromosome cassette (SCCmec) type, presence of toxic shock syndrome toxin (TST), gene ileS-2 for resistant to mupirocin (mupA), and tolerance to chlorhexidine (qacA/B) using standard protocols [7].

Statistical analysis
Overall and baseline colonization status are described based on gender, rank, base of recruitment, age group, time of service in the Peruvian Air Force (≤10 years, 11–20 years, > 20 years), type of activities, smoking status, previous hospitalizations in the last 12 months, previous deployments, use of antibiotics in the last 12 months, previous SSTIs in the last 12 months, previous respiratory diseases, use of corticosteroids in the
last 12 months, place of residence, medical conditions; and is reported as numbers and proportions with two-sided 95% confidence intervals. We also report the prevalence rate of nasal colonization with MRSA strains and the results of the antimicrobial susceptibility for those isolates positive to *Staphylococcus aureus*. We used a logistic regression model to determine the association with the variables listed above. The Institutional Review Boards at USU (Bethesda, MD, USA), and NAMRU-6 (Lima Perú) approved the research protocol.

Results

Demographic and clinical characteristics

We enrolled 756 participants. The mean age of the participants was 30.3 ± 11.5 years, but almost 60% of our study population was younger than 30 years. Slightly more than 80% were male and 61% of the participants had more than 10 years of military service. Almost 90% of the study population included Non-Commissioned officers and troops, and their occupations included administrative (32.5%), instructional (36.5%) and combat (29.2%) activities. We found that 20.1% of the participants had a reported medical condition. Of them, 10% reported gastrointestinal diseases, 5.4% reported a skin disease, 2.6% reported a respiratory disease, and 1.1% reported an infectious disease. More than a third of the participants (34.8%) reported the use of antibiotics during the previous year; of these, 52% (136) gave a specific antibiotic. In addition, 20.2% reported the use of corticosteroids; and 11.6% of the enrolled participants were hospitalized during the previous year. Regarding the diagnosis of any SSTI during the previous year, only 5.8% reported a SSTI. Smoking was common: 34.2% were
current smokers, 16.7 % were past smokers, and 45.6 % reported never smoking (Table 1).

Baseline nasal colonization with Staphylococcus aureus and MRSA

The baseline nasal colonization prevalence among the 756 enrolled participants was 9.7 %. There were two periods of recruitment, in October-November 2013 (655 participants) and April-August 2014 (101 participants), and the baseline nasal colonization rates for each period were similar (9.8 % vs. 8.9 %, \( p = 0.7853 \), Z-statistic for comparison of two proportions). The overall rate of colonization with MRSA was 0.3 % during the study period (2 of 756). These isolates were collected during the 6 month visit at Arequipa, one in a participant enrolled in October 2013 and a second from a different participant who was enrolled in May 2014. Molecular analysis of these MRSA isolates demonstrated that they possessed SCCmec type IV and qacA/B (chlorhexidine tolerance), but lacked genes for PVL, mupirocin resistance, and toxic shock syndrome toxin (TST).

Table 2 shows statistically significant associations between prevalence of nasal colonization at baseline and demographic and clinical variables. Those participants between 18 and 29 years old and 40 to 49 years old had a higher prevalence of nasal colonization (10.2 % vs. 11.3 %); while, the prevalence was lower than 7 % for other age groups. Nasal colonization was greater in males than female (10.3 vs. 6.8 %, \( p = 0.201 \)). The troops had 11.5 % of nasal baseline nasal colonization, higher than officers or non-commissioned officers (9.5 % vs. 8.2 %). There was a statistically significant difference in the distribution of nasal colonization by base of recruitment (\( p = 0.023 \)); Talara had the lowest baseline prevalence (4.3 %) compared to the other three bases that had similar rates (Iquitos-9.1 %, Arequipa-14.0 % and Lima-11.3 %). Those who lived on base but not in the barracks had the lowest prevalence (5.3 %) but this was not significantly (\( p = 0.198 \)) different from those who lived at the barracks (11.2 %) and those who lived off the base (9.9 %).

Having a respiratory disease increases the prevalence of nasal colonization (30 %) compared with those without respiratory disease (9.1 %, \( p = 0.002 \)). Smoking did not affect the prevalence of nasal colonization; the rates were similar among those who never smoked (8.1 %), previous smokers (12.7 %) and currently smokers (10.4 %) (\( p = 0.300 \)) (Table 3).

Among those who used antibiotics during the last year, the nasal colonization prevalence at baseline was not different among those who used them (11.0 %) or not (9.1 %). However, when we analyzed the use of dicloxacillin the previous year, those who reported its use had a 33.3 % prevalence of nasal colonization, compared with those who did not report its use (9.3 %, \( p = 0.005 \)). Regarding the use of corticosteroids, those who used them the previous year, had a prevalence of 12.4 %, which was similar to those who did not use them (8.9 %), \( p = 0.432 \).

In terms of hospitalization during the previous year, the rates were similar among those who were hospitalized (10.2 %) and those who were not (9.6 %) (\( p = 0.971 \)). Similarly there was no difference in prevalence between those who had the diagnosis of SSTIs during the last year (9.1 %) and those who did not (9.5 %). The identified risk factors for S. aureus colonization included being male and a reported history of respiratory disease; while time of service had a slight protective effect.

Antimicrobial susceptibility of positive isolates and MRSA isolates

NAMRU-6 and USUHS labs processed 183 positive Staphylococcus aureus samples from the participants during the study period (1 year). Antimicrobial susceptibility is reported in Table 3. The highest resistance was to erythromycin (16.4 %). In addition, 6.6 % had an inducible resistance to clindamycin. All isolates were susceptible to ceftaroline, trimethoprim-sulfamethoxazole, vancomycin, and linezolid (Table 4).

Discussion

Baseline prevalence

There are only a few studies of nasal colonization in active duty military populations, primarily from the US and one from China, but none in Peru or Latin America. These studies found that the prevalence of colonization in American recruits was 31 % [11], while the Chinese military found a different rate depending if individuals were deployed to urban (24.6 %) or suburban military centers (16.1 %) [21]. In both cases, the prevalence was higher than what we found at baseline in our study population (9.7 %). Only two previous studies were performed in community settings in Peru. One study included only children from Cajamarca and found a prevalence of 11.9 % [22], while the second included inhabitants of an impoverished community of Lima, and found that among adults of different ages the prevalence of nasal colonization ranged from 20.4 to 39.6 % [23]. These two previous studies in Peru are comparable with others studies performed in Latin American countries that showed that the nasal colonization rates with Staphylococcus aureus in community settings was quite varied. In adult populations, the nasal colonization rates in Brazil ranged between 32.7 % [24] and 40.8 % [25]; while among Colombian medical students the rate was 25 % [26]. The prevalence we obtained in the Peruvian military was closer to the prevalence rate reported among adult students in Nigeria (14 %) and healthcare workers in Nicaragua (6.7 to 11.6 %) [27, 28]. In Peru, 3 MRSA strains from Peruvian citizens returning
from abroad were characterized in 2011, one was ST30 and the other two were ST8 clones which are related to the USA300 clone [29].

We found differences in the prevalence of nasal colonization based on the site of the geographical site if study enrollment. Of the four sites, Lima is the capital city of Peru (approximately 10 million inhabitants), while Arequipa (900,000 inhabitants) and Iquitos (420,000 inhabitants) are the most important urban centers in the highlands and the jungle and had higher prevalence rates; while Talara, which is a smaller city than the other three (101,000 inhabitants), had only 4.3 %. This colonization prevalence differences may be attributed to a number of factors including climate and ecology, population size, or access to healthcare. An important aspect of population size is that it generally suggests differences in commercial movement, and therefore access to common antibiotics that are still sold without a medical prescription at small pharmacies and drugstores. Additionally, the distribution of antibiotics to each military health facility is based on the most prevalent diseases and the size of the base, which are larger in Lima, Arequipa and Iquitos where administrative and operational regional offices are located, and therefore exceed

| Variable                  | Frequency | Percentage (%) |
|---------------------------|-----------|----------------|
| Age                       |           |                |
| 18 – 29 years             | 450       | 59.5           |
| 30 – 39 years             | 95        | 12.6           |
| 40 – 49 years             | 151       | 20.0           |
| 50 years or more          | 60        | 7.9            |
| Time of service           |           |                |
| 10 years or less          | 463       | 61.2           |
| 11 – 20 years             | 103       | 13.6           |
| 20 years or more          | 190       | 25.1           |
| Sex                       |           |                |
| Female                    | 146       | 19.3           |
| Male                      | 610       | 80.7           |
| Rank                      |           |                |
| Officers                  | 84        | 11.1           |
| Non-Commissioned Officers | 368       | 48.7           |
| Troops                    | 304       | 40.2           |
| Base of recruitment       |           |                |
| Iquitos                   | 253       | 33.5           |
| Arequipa                  | 164       | 21.7           |
| Talara                    | 162       | 21.4           |
| Lima                      | 177       | 23.4           |
| Administrative activities  |           |                |
| No                        | 510       | 67.5           |
| Yes                       | 246       | 32.5           |
| Instruction activities    |           |                |
| No                        | 483       | 63.9           |
| Yes                       | 273       | 36.1           |
| Combat activities         |           |                |
| No                        | 535       | 70.8           |
| Yes                       | 221       | 29.2           |
| Number of activities      |           |                |
| Not related               | 106       | 14.0           |
| Unique                    | 580       | 76.7           |
| Multiple                  | 70        | 9.3            |
| Place of residence        |           |                |
| Barracks                  | 250       | 33.1           |
| Inside the base           | 114       | 15.1           |
| Outside the base          | 392       | 51.9           |
| Medical conditions        |           |                |
| No                        | 604       | 79.9           |
| Yes                       | 152       | 20.1           |
| Number of medical conditions |       |                |
| None                      | 604       | 79.9           |

Table 1 Demographic characteristics of study participants (Continued)

| Variable                          | Frequency | Percentage (%) |
|-----------------------------------|-----------|----------------|
| One disease                       | 118       | 15.6           |
| More than one disease             | 34        | 4.5            |
| Use of antibiotics in the previous year | | |
| No                                | 427       | 56.5           |
| Yes                               | 263       | 34.8           |
| Unknown                           | 66        | 8.7            |
| Use of corticosteroids in the previous year | | |
| No                                | 536       | 70.9           |
| Yes                               | 153       | 20.2           |
| Unknown                           | 67        | 8.9            |
| Hospitalized during the previous year |       |                |
| No                                | 645       | 85.3           |
| Yes                               | 88        | 11.6           |
| Unknown                           | 23        | 3.0            |
| Diagnosis of SSTIs during the previous year | | |
| No                                | 671       | 88.8           |
| Yes                               | 44        | 5.8            |
| Unknown                           | 41        | 5.4            |
| Smoking status                    |           |                |
| Never                             | 345       | 45.6           |
| Past smoker                       | 126       | 16.7           |
| Current smoker                    | 259       | 34.2           |

Table 1 Demographic characteristics of study participants
| Variable                        | Baseline Nasal colonization (%) | 95 % CI               | P value |
|--------------------------------|---------------------------------|-----------------------|---------|
|                                | Positive (n = 73)               | Negative (n = 683)    |         |
| **Age**                        |                                 |                       |         |
| 18 – 29 years                  | 10.2 (7.4 – 13.0)               | 89.8 (86.9 – 92.6)    | 0.537^a |
| 30 – 39 years                  | 6.3 (1.4 – 11.2)                | 93.7 (88.8 – 96.6)    |         |
| 40 – 49 years                  | 11.3 (6.2 – 16.3)               | 88.7 (83.7 – 93.8)    |         |
| 50 years or more               | 6.7 (0.3 – 13.0)                | 93.3 (86.9 – 99.7)    |         |
| **Time of service**            |                                 |                       |         |
| 10 years or less               | 10.6 (7.8 – 13.4)               | 89.4 (86.6 – 92.2)    | 0.334   |
| 11 – 20 years                  | 5.8 (1.3 – 10.4)                | 94.2 (89.6 – 98.7)    |         |
| 20 years or more               | 9.5 (5.3 – 13.7)                | 90.5 (86.3 – 94.7)    |         |
| **Sex**                        |                                 |                       |         |
| Female                         | 6.8 (2.7 – 10.9)                | 93.2 (89.0 – 97.3)    | 0.201   |
| Male                           | 10.3 (7.9 – 12.7)               | 89.7 (87.3 – 92.1)    |         |
| **Rank**                       |                                 |                       |         |
| Officers                       | 9.5 (3.2 – 15.8)                | 90.5 (84.2 – 96.8)    | 0.340   |
| Non-Commissioned Officers      | 8.2 (5.3 – 10.9)                | 91.8 (89.0 – 94.7)    |         |
| Troops                         | 11.5 (7.9 – 15.1)               | 88.5 (84.9 – 92.1)    |         |
| **Base of recruitment**        |                                 |                       |         |
| Iquitos                        | 9.1 (5.5 – 12.6)                | 90.9 (87.4 – 94.5)    | 0.023   |
| Arequipa                       | 14.0 (8.7 – 19.4)               | 85.9 (80.6 – 91.3)    |         |
| Talara                         | 4.3 (11.8 – 7.5)                | 95.7 (92.5 – 98.8)    |         |
| Lima                           | 11.3 (6.6 – 15.9)               | 88.7 (84.0 – 93.4)    |         |
| **Number of activities**       |                                 |                       |         |
| Not related                    | 10.4 (4.5 – 16.2)               | 89.6 (83.8 – 95.5)    | 0.587   |
| Unique                         | 9.1 (6.8 – 11.5)                | 90.9 (88.5 – 93.2)    |         |
| Multiple                       | 12.9 (4.9 – 20.8)               | 87.1 (79.2 – 95.1)    |         |
| **Number of medical conditions** |                                 |                       |         |
| None                           | 9.9 (7.5 – 12.3)                | 90.1 (87.7 – 92.5)    | 0.122   |
| One disease                    | 6.1 (1.7 – 10.5)                | 93.9 (89.5 – 98.3)    |         |
| More than one disease          | 17.6 (4.6 – 30.7)               | 82.4 (69.3 – 95.4)    |         |
| **Respiratory diseases the previous year** |             |                       |         |
| No                             | 9.1 (7.0 – 11.2)                | 90.9 (88.8 – 92.9)    | 0.002   |
| Yes                            | 30.0 (9.4 – 50.6)               | 70.0 (49.4 – 90.6)    |         |
| **Use of antibiotics the previous year** |               |                       |         |
| No                             | 9.1 (6.4 – 11.9)                | 90.9 (88.1 – 93.6)    | 0.598   |
| Yes                            | 11.0 (7.2 – 14.8)               | 88.9 (85.2 – 92.8)    |         |
| Unknown                        | 7.6 (11.3 – 14.0)               | 92.4 (85.9 – 98.9)    |         |
| **Use of dicloxacillin previous year** |                     |                       |         |
| No                             | 9.3 (7.2 – 11.4)                | 90.7 (88.6 – 92.8)    | 0.005   |
| Yes                            | 33.3 (5.4 – 61.2)               | 66.7 (38.8 – 94.6)    |         |
| **Use of corticosteroids the previous year** | |                       |         |
| No                             | 8.9 (6.5 – 11.4)                | 91.0 (88.6 – 93.5)    | 0.432   |
| Yes                            | 12.4 (7.2 – 17.7)               | 87.6 (82.3 – 92.8)    |         |
| Unknown                        | 8.9 (2.1 – 15.9)                | 91.0 (84.1 – 97.9)    |         |
the population assigned to Talara, which is only an operational base. The increased exposure to antibiotics in Lima, Iquitos and Arequipa might favor the development of nasal colonization with *Staphylococcus aureus* by eliminating other commensal bacteria colonizing the human nares; unfortunately information regarding the most used antibiotics at each of the bases or local areas is currently unavailable.

Dicloxacillin is an antibiotic belonging to the beta lactam family that is used extensively for the treatment of SSTIs. We had expected that the use of dicloxacillin might reduce the rates of nasal colonization with *Staphylococcus aureus*, but we found the opposite. Possibly, the normal microbiota in the anterior nares is more susceptible than *Staphylococcus aureus* to dicloxacillin, therefore favoring the *Staphylococcus aureus* growth. Another possible reason can be the misuse of this antibiotic, which is usually prescribed for 7 to 14 days, but if the dose and time of prescription were not adequate, the antibiotic might have limited effect. We were not able to collect information regarding the dose, time of prescription, where the antibiotics were purchased, or if the treatment was completed.

We identified only two participants with MRSA and therefore our overall prevalence of MRSA colonization during the study period was 0.3 % (2 of 756). These isolates possessed SCCmec type IV which is the characteristic mobile genetic element carrying the mecA gene (methicillin-resistance) found most commonly in CA-MRSA strains. Our MRSA colonization prevalence was close to those reported in previous studies in Peru and Latin America, where it ranges from 0.6 to 1.8 % [23, 30, 31] in communities; however these proportions are lower than those observed in developed countries like US or Europe. In terms of military populations, our results reflect that MRSA nasal colonization is lower than rates reported in US military populations (3 %), while the Chinese study did not detect any MRSA [11, 21].

Our questionnaire was not designed to provide more specific historical information regarding the type of SSTI and treatments prescribed, dose and timing of antibiotics and corticosteroids, time of hospitalization, place, and antibiotics used during this time, which could have given us more detailed information regarding these risk factors. Also, given that this was a self-administered questionnaire, there is the potential for recall bias. In addition, it is possible that some participants did not understand the questions asked or did not know the medical terms used; therefore they left the questions blank. In addition, it is possible that sample handling could have affected the recovery of positive *S. aureus* isolates, specifically during the sampling procedure due to discomfort of the participants that led to movements of the head and a poor quality sample, and the limited available timeframe we had for doing it. Different climate conditions at each site may have affected also the recovery due to the use of a refrigerated container that could not have kept a low temperature at all times.

We believe our results can serve as a proxy to understanding of the nasal colonization with *Staphylococcus*
in the community. We found that these isolates have a remarkable antimicrobial susceptibility with very little resistance when compared with other populations. This susceptibility may allow us an optimization of the current treatment of different infections where Staphylococcus aureus is a common etiologic agent. This standardization should help to reduce the indiscriminate exposure to more expensive and broader spectrum antibiotics that should be left as second or third line options, which are more expensive and increase the risk of adverse reactions.

Conclusions
In summary, we found a low prevalence of baseline nasal colonization with Staphylococcus aureus (9.7 %) and MRSA (0.3 %) in an active duty military population in Peru. Our results increase the current knowledge about Staphylococcus aureus nasal colonization in Peru and Latin America. Further study exploring the geographically differences in S. aureus nasal colonization warrants further investigation.

Abbreviations
AMR, Antimicrobial resistance; MRSA, methicillin-resistant Staphylococcus aureus; SCCmec, staphylococcal cassette chromosome mec

Acknowledgments
None.

Funding
This research was funded by the Global Emerging Infections Surveillance and Response System (GEIS) of the Armed Forces Health Surveillance Branch. Ref, Number: P0004_12_HS.

Availability of data and materials
Data will not be shared since participants belong to the Peruvian Armed Forces and it contains sensitive information.

Authors’ contributions
JN was responsible for developing the study protocol, obtaining IRB approval, overseeing the implementation of the study, coordinating and providing general oversight to all research efforts and performed data collection and analysis. DB oversaw the implementation of the study protocol as well as the manuscripts writing. ME was responsible for sample testing, sequencing and characterization of MRSA strains at USUHS. CR provided oversight of the laboratory diagnostic procedures at NAMRU-6 and helped during the sample collection at the study sites. MA was in charge of coordination with the Peruvian Air Force, provided general oversight to the data collection from all the Peruvian Air Force establishments. JS helped with the sample collection at the study sites and with the coordination for data collection of SSTIs at each health establishment. RM, YM, MB, EC performed the sample identification, molecular tests and antimicrobial susceptibility tests at NAMRU-6 Bacteriology labs. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Table 3 Potential risk factors associated with baseline nasal colonization with Staphylococcus aureus

| Variable                          | N    | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | P-value |
|----------------------------------|------|------------------------|----------------------|---------|
| Use of antibiotics during the previous year |      |                        |                      |         |
| No                               | 400  | Ref                    | Ref                  |         |
| Yes                              | 238  | 1.2                    | 1.4 (0.8 – 2.6)      | 0.283   |
| Hospitalization during the previous year |      |                        |                      |         |
| No                               | 566  | Ref                    | Ref                  |         |
| Yes                              | 72   | 1.0                    | 1.0 (0.4 – 2.4)      | 0.980   |
| Diagnosis of SSTI during the previous year |      |                        |                      |         |
| No                               | 600  | Ref                    | Ref                  |         |
| Yes                              | 38   | 0.5                    | 0.4 (0.1 – 1.8)      | 0.237   |
| Sex                              |      |                        |                      |         |
| Female                           | 122  | Ref                    | Ref                  |         |
| Male                             | 516  | 1.8                    | 2.4 (1.0 – 5.7)      | 0.043   |
| Base of recruitment              |      |                        |                      |         |
| Talara                           | 144  | Ref                    | Ref                  |         |
| Iquitos                          | 207  | 2.5                    | 2.5 (0.9 – 6.5)      | 0.065   |
| Lima                             | 149  | 2.8                    | 2.7 (0.9 – 7.3)      | 0.051   |
| Arequipa                         | 138  | 3.9                    | 4.5 (1.7 – 11.9)     | 0.002   |
| Smoking status                   |      |                        |                      |         |
| Never smoked                     | 312  | Ref                    | Ref                  |         |
| Past smoker                      | 107  | 1.7                    | 1.6 (0.8 – 3.5)      | 0.204   |
| Current smoker                   | 219  | 1.2                    | 1.1 (0.6 – 2.1)      | 0.756   |
| Respiratory diseases             |      |                        |                      |         |
| No                               | 619  | Ref                    | Ref                  |         |
| Yes                              | 19   | 3.5                    | 4.5 (1.4 – 14.7)     | 0.014   |
| Time of service                  | 638  | 0.99                   | 0.97 (0.94 – 0.99)   | 0.030   |

Table 4 Antimicrobial susceptibility of 183 Staphylococcus aureus isolates

| Antibiotic     | Number (% of samples) | Susceptible | Resistant | Intermediate |
|----------------|------------------------|-------------|-----------|--------------|
| Clindamycin*   | 179 (97.8)             | 4 (2.2)     | -         |              |
| Erythromycin   | 153 (83.6)             | 30 (16.4)   | -         |              |
| Doxycycline    | 180 (98.4)             | -           | 3 (1.6)   |              |
| Linezolid      | 183 (100)              | -           | -         |              |
| Oxacillin      | 181 (98.9)             | 2 (1.1)     | -         |              |
| Rifampin       | 183 (100)              | -           | -         |              |
| TMP-SMX b      | 183 (100)              | -           | -         |              |
| Vancomycin     | 183 (100)              | -           | -         |              |
| Gentamicin     | 177 (96.7)             | 6 (3.3)     | -         |              |
| Levofloxacin   | 182 (99.5)             | 1 (0.5)     | -         |              |
| Ceftaroline    | 183 (100)              | -           | -         |              |

* 6.6 % of the samples showed inducible resistance to clindamycin
bTMP-SMX, trimethoprim-sulfamethoxazole
Consent for publication
We report aggregated data from the participants. During the consent process we asked for consent to publish form the participants.

Ethics approval and consent to participate
The protocol was approved by the Institutional Review Board of U.S. Naval Medical Research Unit No. 6, Lima-Peru (NAMRU-6), Ref. number NAMRU6.2013.0021.
Each study participant signed an informed consent previous to enrollment.

Author details
1Naval Medical Research Unit N° 6-Lima-Peru (NAMRU-6), 655 Manco Capac St., Miraflores, Lima, Peru. 2University of Toledo College of Medicine and Life Sciences, Toledo, USA. *Peruvian Air Force, Lima, Peru. 2Uniformed Services University (USU), Bethesda, USA.

Received: 5 March 2016 Accepted: 7 June 2016
Published online: 22 July 2016

References
1. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616–87.
2. Wallin TR, Hern HG, Frazee BW. Community-associated methicillin-resistant Staphylococcus aureus: Emerg Med Clin North Am. 2008;26(2):431–55. ix.
3. Tenover FC, McAllister S, Fosheim G, McDougal LK, Carey RB, Limbago B, Loria-Silva D, Patel JB, Kuehnert MJ, Gorbitz R. Characterization of Staphylococcus aureus isolates from nasal cultures collected from individuals in the United States in 2001 to 2004. J Clin Microbiol. 2008;46(9):2837–41.
4. Kluymans JA, Mouton JW, Izerman EP, Vandenbergroucke-Grauls CM, Maat AW, Wagenhoort JH, Verbrugh HA. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis. 1995;171(1):216–9.
5. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage of methicillin-resistant Staphylococcus aureus isolates from nasal cultures collected from individuals in the United States in 2001 to 2004. J Clin Microbiol. 2008;46(9):2837–41.
6. Boyce J. Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults. In: June 16, 2010 edn: UpToDate 2010, 2010.
7. Ellis MW, Griffith ME, Jorgensen JH, Hospenthal DR, Mende K, Patterson JE. Presence and molecular epidemiology of virulence factors in methicillin-resistant Staphylococcus aureus strains colonizing and infecting soldiers. J Clin Microbiol. 2009;47(4):940–5.
8. Frank DN, Feazel LM, Bessesen MT, Price CS, Janoff BN, Pace NR. The human nasal microbiota and Staphylococcus aureus carriage. PLoS One. 2010;5(6):e10598.
9. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5(12):751–62.
10. Solid JU, Furberg AS, Hansen AM, Johanssene M. Staphylococcus aureus determinants of human carriage. Infect Genet Evol. 2014;21:531–41.
11. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis. 2004;39(7):971–9.
12. Mehdinratra PL, Bhatta P. Typing of Methicillin resistant Staphylococcus aureus: a technical review. Indian J Med Microbiol. 2012;30(1):16–23.
13. Patel M. Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management. Drugs. 2009;69(8): 693–716.
14. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother. 2009;64(3):441–6.
15. Control CID. Antibiotic Resistance Threats in the United States, 2013. 2013:114.
16. Organization WH. Antimicrobial Resistance. Global Report on Surveillance 2014. 2014:232.
17. Lee BY, Singh A, David MZ, Bartsch SM, Slayton RB, Huang SS, Zimmer SM, Pappas MA, Macal CM, Lauderdale DS, et al. The economic burden of community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect. 2013;19(6):528–36.
18. Mejia C, Zurrutia J, Guzman-Blanco M. Epidemiology and surveillance of meticillin-resistant staphylococcus aureus in Latin America. Braz J Infect Dis. 2010;14 Suppl 2:579–86.